Expression of the lung resistance protein in primary colorectal carcinomas
Pohl, G.; Suchomel, R.W.; Stranzl, T.; Depisch, D.; Stiglbauer, W.; Filipits, M.; Pirker, R.
Anticancer Research 21(1a): 201-204
2001
ISSN/ISBN: 0250-7005 PMID: 11299735 Document Number: 538668
To assess whether the lung resistance protein (LRP) is of clinical significance in colorectal carcinomas, we immunohistochemically determined LRP expression of colorectal carcinoma specimens (n = 68) by means of the monoclonal antibody LRP-56 and compared this expression with clinical parameters. LRP expression was negative in 7 (10%), low in 36 (52%) and high in 25 (38%) carcinomas. LRP expression was independent of histological grade, tumor size, lymph node involvement and distant metastasis. Survival of the patients with LRP-positive tumors was similar to the survival of patients with LRP-negative tumors. However, patients with high LRP expression in their carcinomas had a prolonged survival. Thus LRP is frequently expressed in colorectal carcinomas and high expression might indicate improved survival.